Kristian Stengaard-Pedersen

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • S B Krintel
  • ,
  • C Dehlendorff
  • ,
  • M L Hetland
  • ,
  • K Hørslev-Petersen
  • ,
  • K K Andersen
  • ,
  • P Junker
  • ,
  • J Pødenphant
  • ,
  • T Ellingsen
  • ,
  • P Ahlquist
  • ,
  • H M Lindegaard
  • ,
  • A Linauskas
  • A Schlemmer
  • MY Dam
  • ,
  • I Hansen
  • H C Horn
  • ,
  • A Jørgensen
  • ,
  • J Raun
  • ,
  • C G Ammitzbøll
  • ,
  • M Østergaard, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark
  • ,
  • K Stengaard-Pedersen
  • J S Johansen, Department of Oncology, Herlev University Hospital, Herlev

At least 30% of patients with rheumatoid arthritis (RA) do not respond to biologic agents, which emphasizes the need of predictive biomarkers. We aimed to identify microRNAs (miRNAs) predictive of response to adalimumab in 180 treatment-naïve RA patients enrolled in the OPtimized treatment algorithm for patients with early RA (OPERA) Study, an investigator-initiated, prospective, double-blind placebo-controlled study. Patients were randomized to adalimumab 40 mg (n=89) or placebo-adalimumab (n=91) subcutaneously in combination with methotrexate. Expressions of 377 miRNAs were determined using TaqMan Human MicroRNA LDA, A Card v2.0 (Applied Biosystems). Associations between miRNAs and treatment response were tested using interaction analyses. MiRNAs with a P-value <0.05 using three different normalizations were included in a multivariate model. After backwards elimination, the combination of low expression of miR-22 and high expression of miR-886.3p was associated with EULAR good response. Future studies to assess the utility of these miRNAs as predictive biomarkers are needed.The Pharmacogenomics Journal advance online publication, 5 May 2015; doi:10.1038/tpj.2015.30.

Original languageEnglish
JournalPharmacogenomics Journal
Volume16
Issue2
Pages (from-to)141-6
Number of pages6
ISSN1470-269X
DOIs
Publication statusPublished - 2016

See relations at Aarhus University Citationformats

ID: 96323860